Free Trial
NASDAQ:TLPH

Talphera Q1 2026 Earnings Report

Talphera logo
$0.90 +0.01 (+1.39%)
Closing price 05/5/2026 04:00 PM Eastern
Extended Trading
$0.90 -0.01 (-0.76%)
As of 09:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Talphera EPS Results

Actual EPS
N/A
Consensus EPS
-$0.07
Beat/Miss
N/A
One Year Ago EPS
N/A

Talphera Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Talphera Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call Date
Wednesday, May 13, 2026
Conference Call Time
4:30PM ET

Conference Call Resources

Talphera Earnings Headlines

I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, Amazon, Snap, and Block have done the same. Most assume this is about AI - but investor Porter Stansberry says the real driver runs far deeper. Goldman Sachs estimates 12,400 Americans are being financially harmed every day by this shift, while others grow wealthier. Stansberry - who predicted the internet economy's rise and recommended Amazon, Qualcomm, and Texas Instruments before they were household names - is now releasing a new investigation he calls The Final Displacement.tc pixel
Talphera, Inc. (TLPH) Analyst/Investor Day Transcript
See More Talphera Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Talphera? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Talphera and other key companies, straight to your email.

About Talphera

Talphera (NASDAQ:TLPH), a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

View Talphera Profile